- Home
- SISI vs COEP Comparison
SISI vs COEP Comparison
Compare SISI & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- COEP
- Stock Information
- Founded
- SISI 1997
- COEP 2017
- Country
- SISI China
- COEP United States
- Employees
- SISI N/A
- COEP N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SISI Health Care
- COEP Health Care
- Exchange
- SISI Nasdaq
- COEP Nasdaq
- Market Cap
- SISI 7.0M
- COEP 8.0M
- IPO Year
- SISI 2016
- COEP N/A
- Fundamental
- Price
- SISI $0.45
- COEP $0.19
- Analyst Decision
- SISI
- COEP Strong Buy
- Analyst Count
- SISI 0
- COEP 1
- Target Price
- SISI N/A
- COEP $3.00
- AVG Volume (30 Days)
- SISI 1.5M
- COEP 155.3K
- Earning Date
- SISI 11-12-2024
- COEP 11-07-2024
- Dividend Yield
- SISI N/A
- COEP N/A
- EPS Growth
- SISI N/A
- COEP N/A
- EPS
- SISI N/A
- COEP N/A
- Revenue
- SISI $5,623,122.00
- COEP N/A
- Revenue This Year
- SISI N/A
- COEP N/A
- Revenue Next Year
- SISI N/A
- COEP N/A
- P/E Ratio
- SISI N/A
- COEP N/A
- Revenue Growth
- SISI N/A
- COEP N/A
- 52 Week Low
- SISI $0.33
- COEP $0.17
- 52 Week High
- SISI $4.90
- COEP $1.38
- Technical
- Relative Strength Index (RSI)
- SISI 41.50
- COEP 36.43
- Support Level
- SISI $0.37
- COEP $0.18
- Resistance Level
- SISI $0.50
- COEP $0.22
- Average True Range (ATR)
- SISI 0.05
- COEP 0.01
- MACD
- SISI 0.03
- COEP 0.00
- Stochastic Oscillator
- SISI 31.04
- COEP 12.20
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed over 33 vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.